TICKERNERD
Menu
CLBTCLBTTechnology · Software - Infrastructure

CLBT Stock Forecast: Cellebrite DI Ltd. Price Predictions for 2026-2027

Last close, 4 Sept 2026
$11
−4.10% on the day

The 8 Wall Street analysts covering Cellebrite DI Ltd. hold a median 12-month price target of $15 — +31.0% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 49 of 100 as at 5 Sept 2026 — in the lower half.

Market cap
$2.9B
Ticker Nerd rank
49 / 100
Median analyst target
$15
Analysts covering
8
Revenue$131.1M+15.8% y/y
Operating income$6.9M
Net income$6.4M
Free cash flow$6.0M
Quarterly, 8 quarters to 30 June 2026 · latest quarter's figure shown
Total return, dividends reinvested
1W
−4.5%
1M
−27.4%
YTD
−36.5%
1Y
−30.1%
From 52W high
−41.5%
From 52W low
+9.7%
$10
$20
52-week range, adjusted closes · the dot is the last close
Ticker Nerd rank

CLBT stock analysis: one number for the whole business

Consensus tells you what everyone already believes. The model scores Cellebrite DI Ltd. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 5 Sept 2026
49 / 100

Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Quality
91
Growth
69
Accruals
63
Value
60
Momentum
39
Revisions
38
Volatility
37
Issuance
36
Size
32

Quality (91): The business earns solid, repeatable profits on what it owns.

Issuance (36): The company has been issuing shares or taking on financing, diluting existing holders.

Size (32): Larger than most of the companies we track — more scrutinised, less often mispriced.

Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.

Wall Street

CLBT stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on CLBT, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, 12 monthsAdjusted close, US dollars
$10$12$14$16$18$20Oct 25Jan 26Apr 26Jul 26CLBTHigh $20Median $15Low $13

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Data provided by Twelve Data

What Wall Street says8 analysts
8 Buy0 Hold0 Sell
Low $13Median $15High $20

The green dot is the last close — the median target sits +31.0% from it.

Recent analyst actionsNewest first

Of the 20 most recent actions, 1 moved their price target up and 4 moved it down.

DateFirmActionRatingTarget
14 Aug 2026DA DavidsonMaintainsBuy$22 → $15
14 Aug 2026JP MorganMaintainsOverweight$20 → $16
14 Aug 2026Lake StreetMaintainsBuy$21 → $15
14 Aug 2026NeedhamMaintainsBuy$15 → $13
6 Aug 2026DA DavidsonMaintainsBuy—
6 Aug 2026DA DavidsonMaintainsBuy$20 → $22
27 May 2026DA DavidsonInitiatesBuy$20
27 May 2026DA DavidsonInitiatesBuy—
15 May 2026NeedhamMaintainsBuy—
12 Feb 2026NeedhamMaintainsBuy—
13 Nov 2025B of A SecuritiesMaintainsBuy—
13 Nov 2025JP MorganMaintainsOverweight—
13 Nov 2025Lake StreetMaintainsBuy—
13 Nov 2025NeedhamMaintainsBuy—
24 Sept 2025JP MorganMaintainsOverweight—
15 Aug 2025Lake StreetMaintainsBuy—
14 Aug 2025NeedhamMaintainsBuy—
23 June 2025JP MorganMaintainsOverweight—
6 June 2025NeedhamReiteratesBuy—
15 May 2025JP MorganMaintainsOverweight—

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Market Radar

This page is one stock. Monday covers all of them.

Computed off the Friday close and sent before the US open.

Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. CLBT appears on the weeks it earns a place.

Free, every Monday. Unsubscribe any time.

Performance

CLBT vs the S&P 500

Both lines are total return — dividends reinvested — so the comparison is honest on both sides.

Over the twelve months to 4 Sept 2026, Cellebrite DI Ltd. returned −30.1% against +20.0% for the S&P 500, dividends included.

CLBT vs S&P 500, last 12 monthsTotal return, rebased to 100
60708090100110120Oct 25Jan 26Apr 26Jul 26CLBTS&P 500

Download this chart as an image — free to reuse; link this page as the source.

Data provided by Twelve Data

Estimates

CLBT analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingNext fiscal year
EPS revision, 90 days
−1.2%
Analysts raising
3
Analysts cutting
4
Fundamentals

Cellebrite DI Ltd. (CLBT) financial data

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
49.8×

Cheaper than 14% of US stocks

Price / sales
5.6×

Cheaper than 23% of US stocks

Price / book
5.3×

Cheaper than 20% of US stocks

EV / EBITDA
31.3×

Cheaper than 8% of US stocks

Growth & margins
Revenue growth (YoY)
15.8%

Higher than 64% of US stocks

Earnings growth (YoY)
−67.3%

Higher than 7% of US stocks

Gross margin
80.8%

Higher than 91% of US stocks

Operating margin
5.3%

Higher than 56% of US stocks

Net margin
11.4%

Higher than 72% of US stocks

Returns & dividend
Return on equity
12.4%

Higher than 69% of US stocks

Return on assets
3.9%

Higher than 71% of US stocks

Dividend yield
—

Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.

Key statistics

Cellebrite DI Ltd. (CLBT) statistics: revenue, profit & scale

The headline figures, each with its date. Every row carries its own link — cite it straight from here.

  • Cellebrite DI Ltd. has a market value of $2.9B and an enterprise value of $2.5B.

  • Revenue in the twelve months to 30 June 2026: $514.3M. The latest quarter grew 15.8% year on year.

  • Net income over the same four quarters: $58.8M, a 11.4% net margin.

  • Diluted earnings per share, trailing twelve months: $0.22.

  • Free cash flow in the twelve months to 30 June 2026: $128.6M.

  • Shares outstanding: 250.8M.

  • Trailing P/E: 49.8×; forward P/E: 17.5× — the forward figure prices analyst consensus estimates, not reported earnings.

  • Cellebrite DI Ltd. employs 1,285 people — $400K of revenue per employee.

Statement figures: company filings via Twelve Data, four quarters to 30 June 2026 · market figures as at 8 Sept 2026

Data provided by Twelve Data

Peers

CLBT vs competitors

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelSoftware - Infrastructure
CompanyMarket capTKN rank
CLBTCellebrite DI Ltd.$2.9B
49
INFQInfleqtion, Inc.$2.8B
18
EEFTEuronet Worldwide, Inc.$2.8B
57
NTCTNetScout Systems, Inc.$2.7B
95
PAGSPagSeguro Digital Ltd.$2.8B
68
APPNAppian Corp.$2.8B
97
AVPTAvePoint, Inc.$2.8B
69

Look up any of the roughly 4,600 stocks we score.

The rank is the raw material. Whether the rules would actually own Cellebrite DI Ltd. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

News

Latest CLBT news & analysis

Kaplan Fox Encourages Investors of Cellebrite DI Ltd. (CLBT) to Contact the Firm to Learn About Their Legal Rights

Newsfile Corp · 4 Sept 2026negative

Kaplan Fox & Kilsheimer LLP announced it is investigating potential securities violations against Cellebrite DI Ltd. The firm is encouraging investors in the company to contact them to learn about their legal rights.

Why it matters — A securities investigation raises the possibility of regulatory or legal exposure for Cellebrite, which could affect investor confidence in the stock.

Cellebrite Announces Upcoming Investor Events in September

PRNewsWire · 4 Sept 2026neutral

Cellebrite announced that it will participate in upcoming investor events scheduled for September, with the announcement released from its offices in Tysons Corner, Virginia, and Petah Tikva, Israel. The company did not disclose specific financial results or forecasts in this announcement.

Why it matters — Investor events give Cellebrite an opportunity to present its business outlook and strategy to the investment community, so a watcher would monitor these appearances for updates on company performance and direction.

Kaplan Fox is Investigating Cellebrite DI Ltd. (CLBT) for Potential Violations of the Federal Securities Laws

Newsfile Corp · 2 Sept 2026negative

Kaplan Fox & Kilsheimer LLP announced it is investigating potential violations of federal securities laws against Cellebrite DI Ltd. (NASDAQ: CLBT). The investigation was disclosed by the law firm in a September 2, 2026 release.

Why it matters — A securities law investigation introduces legal and regulatory uncertainty for Cellebrite that CLBT watchers may need to monitor.

Cellebrite: Mobile Forensics Leadership At A Compelling Valuation

Seeking Alpha · 2 Sept 2026positive

Seeking Alpha highlights Cellebrite's leadership in mobile forensics, which it says is anchored by roughly 90% recurring revenue and 117% net retention. The analysis points to cross-selling opportunities and a narrow moat as key attributes of the company's profile.

Why it matters — A CLBT watcher would care because the piece affirms the company's dominant position in its core mobile forensics market and highlights the strength of its recurring, retention-heavy revenue model and expansion potential.

Cellebrite Guardian Completes IRAP Assessment: Achieves PROTECTED Level for Australian Government Agencies

PRNewsWire · 2 Sept 2026positive

Cellebrite announced that its Guardian product has completed an IRAP assessment, achieving the PROTECTED level for Australian government agencies. This enables Australian law enforcement, defense, and national security agencies to collaborate and manage digital evidence in the cloud securely on the platform.

Why it matters — The certification opens the door to Australian government and defense agencies as customers for Cellebrite's cloud-based digital evidence platform, potentially broadening its public-sector market reach.

FAQ

Frequently asked questions about CLBT stock

What is the CLBT stock price forecast for 2026-2027?

The 8 Wall Street analysts covering Cellebrite DI Ltd. have a median 12-month price target of $15, with estimates ranging from $13 to $20. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.

Is CLBT stock a buy right now?

Of the 8 analysts covering Cellebrite DI Ltd., 8 rate it a Buy, 0 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Cellebrite DI Ltd. 49 out of 100 across roughly 4,600 US stocks as at 5 Sept 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank CLBT?

As at 5 Sept 2026, Cellebrite DI Ltd. ranks 49 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Quality (91 of 100).

Will CLBT stock go up?

No one can know that. What the data says: the median 12-month target from 8 analysts implies +31.0% from the last close, and Ticker Nerd's factor model ranks Cellebrite DI Ltd. 49 out of 100 as at 5 Sept 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.

What is the CLBT stock forecast for 2030?

No analyst covering Cellebrite DI Ltd. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for CLBT are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $13 to $20 over the next 12 months.

How has CLBT stock performed over the past year?

Cellebrite DI Ltd. returned -30.1% over the 12 months to 4 Sept 2026, with dividends reinvested. Past performance does not indicate future returns.

What does Cellebrite DI Ltd. do?

Cellebrite DI Ltd. is a digital intelligence software company that provides tools for legally sanctioned investigations across public and private sector environments.

What is the latest news on CLBT?

The most recent item we track (Newsfile Corp, 4 Sept 2026): "Kaplan Fox Encourages Investors of Cellebrite DI Ltd. (CLBT) to Contact the Firm to Learn About Their Legal Rights". Kaplan Fox & Kilsheimer LLP announced it is investigating potential securities violations against Cellebrite DI Ltd. The firm is encouraging investors in the company to contact them to learn about their legal rights.

Company

About Cellebrite DI Ltd.

Cellebrite DI Ltd. is a digital intelligence software company that provides tools for legally sanctioned investigations across public and private sector environments. Cellebrite DI Ltd. offers a platform used to access, collect, review, extract, decode, decrypt, analyze, share, and manage digital evidence throughout the investigative process. Its products and services support law enforcement, government agencies, and enterprise customers handling complex cases involving mobile devices, cloud data, and other digital sources. The company also provides training, advisory, advanced services, and technical support to help customers use its investigative workflows effectively. Cellebrite DI Ltd. serves a broad range of use cases, including cybercrime, financial crime, organized crime, counterterrorism, border control, and corporate investigations, making it an important provider in the digital forensics and investigative technology market.

CEO Mr. Shiven Ramji · 1,285 employees · Israel · https://www.cellebrite.com